Noninvasive Prediction of Clinically Significant Portal Hypertension in Hepatocellular Carcinoma: A Tumor-Adjusted Model.

Authors

Coskun O Demirtas, Catherine Mezzacappa, Riccardo Sartoris, Pierre-Emmanuel Rautou, Mario Romero-Cristóbal, Rafael Bañares, Cosmina Sutac, Bogdan Procopet, Manon Allaire, Dominique Thabut, Elba Llop, Juan C García-Pagan, Muthukumarassamy Rajakannu, Eric Vibert, Tamar Taddei, Guadalupe Garcia-Tsao

Published in

The American journal of gastroenterology. Sep 17, 2026. Epub Sep 17, 2026.

Abstract

Noninvasive assessment of clinically significant portal hypertension (CSPH) using liver stiffness measurement (LSM) and platelet count (per Baveno VII criteria) may be influenced by tumor-related factors in patients with hepatocellular carcinoma (HCC). We evaluated the relationship between LSM and hepatic venous pressure gradient (HVPG) and developed a tumor-adjusted model for CSPH prediction in HCC.
In this multicenter study, 452 patients with compensated cirrhosis and HCC who underwent LSM and HVPG within three months were retrospectively analyzed. The correlation between LSM and HVPG was assessed, including stratification by tumor characteristics. A tumor-adjusted predictive model (Baveno-HCC) was developed in a derivation cohort (n=316) and validated in a separate cohort (n=136).
LSM correlated moderately with HVPG (r=0.593, p<0.001), with reduced accuracy in patients with large (>5 cm) right-lobe tumors. Baveno VII criteria maintained high sensitivity and negative predictive value (>90%) for ruling out CSPH but showed limited rule-in performance, particularly in patients with larger tumors. The Baveno-HCC model, incorporating LSM, platelet count, spleen size, and tumor burden, improved rule-in performance with higher positive predictive value (PPV) while preserving rule-out accuracy. Improvements were most pronounced in patients with tumor burden >5 cm, with PPV increasing from 46.2% to 84.6% in the derivation cohort and from 56.3% to 100.0% in the validation cohort.
Tumor burden and location affect LSM-based CSPH assessment. The proposed Baveno-HCC model improves CSPH prediction and supports more accurate risk stratification and clinical decision-making in patients with HCC.

PMID:
42750637
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.